8-K: Celcuity Submits Gedatolisib NDA for Advanced Breast Cancer

Celcuity Inc. announced the submission of its New Drug Application to the U.S. FDA for gedatolisib in HR+/HER2PIK3CA wild-type advanced breast cancer.

Summary

• Celcuity Inc. submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for gedatolisib for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), PIK3CA wild-type advanced breast cancer (ABC).
• The NDA was submitted under the FDA's Real-Time Oncology Review (RTOR) program, which aims to facilitate shorter regulatory review periods.
• Gedatolisib previously received both Breakthrough Therapy and Fast Track designations based on promising preliminary clinical data.
• The submission is based on positive clinical data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial.
• The gedatolisib-triplet (gedatolisib, fulvestrant, and palbociclib) reduced the risk of disease progression or death by 76% compared to fulvestrant, based on a hazard ratio of 0.24.
• The median progression-free survival (PFS) for the gedatolisib-triplet was 9.3 months versus 2.0 months with fulvestrant, an incremental improvement of 7.3 months.
• The gedatolisib-doublet (gedatolisib and fulvestrant) reduced the risk of disease progression or death by 67% compared to fulvestrant, based on a hazard ratio of 0.33.
• The median PFS for the gedatolisib-doublet was 7.4 months versus 2.0 months with fulvestrant, an incremental improvement of 5.4 months.

Sentiment

Score: 9

Explanation: The filing announces a major positive milestone (NDA submission) for a key drug candidate with strong Phase 3 efficacy data, accepted into an expedited FDA review program, and holding Breakthrough Therapy/Fast Track designations. This indicates significant progress towards commercialization and potential market impact, warranting a high sentiment score.

Positives

• Submission of the New Drug Application (NDA) to the FDA for gedatolisib, a significant regulatory milestone.
• The NDA was accepted into the FDA's Real-Time Oncology Review (RTOR) program, which is designed to facilitate shorter regulatory review periods.
• Gedatolisib previously received both Breakthrough Therapy and Fast Track designations, indicating its potential to address unmet medical needs.
• Strong efficacy results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial.
• The gedatolisib-triplet reduced the risk of disease progression or death by 76% (hazard ratio of 0.24) and achieved a median PFS of 9.3 months, an incremental improvement of 7.3 months over fulvestrant.
• The gedatolisib-doublet reduced the risk of disease progression or death by 67% (hazard ratio of 0.33) and achieved a median PFS of 7.4 months, an incremental improvement of 5.4 months over fulvestrant.
• Management believes the efficacy results and overall safety profile of the gedatolisib regimens are potentially practice-changing for patients with HR+/HER2advanced breast cancer.
• Gedatolisib's mechanism of action as a multi-target PI3K/AKT/mTOR (PAM) inhibitor is highly differentiated, offering comprehensive blockade of the PAM pathway.

Negatives

• Gedatolisib is still an investigational drug and has not yet received regulatory approval.
• The forward-looking statements section highlights inherent risks and uncertainties associated with clinical development and regulatory approval processes.

Risks

• Clinical results are based on an ongoing analysis of key efficacy and safety data, and interpretation of such data may change.
• Unforeseen delays in the review of the NDA for gedatolisib by the FDA.
• Ability to obtain and maintain regulatory approvals to commercialize gedatolisib.
• Other risks detailed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the Securities and Exchange Commission.

Future Outlook

Management looks forward to working with the FDA during the NDA review process and believes the unprecedented efficacy results and overall safety profile of the gedatolisib regimens are potentially practice-changing for patients with HR+/HER2advanced breast cancer. The company expects to obtain FDA approval under the RTOR program and to commercialize gedatolisib, though these expectations are subject to a number of risks, uncertainties, and factors.

Management Comments

• "This NDA submission is an important milestone, and it brings gedatolisib one step closer to becoming available for patients with HR+/HER2advanced breast cancer."
• "We look forward to working with the FDA during the NDA review process."
• "We believe the unprecedented efficacy results and overall safety profile of the gedatolisib regimens are potentially practice changing for patients with HR+/HER2advanced breast cancer."

Industry Context

Celcuity operates in the clinical-stage biotechnology sector, focusing on targeted therapies for oncology. The submission of an NDA for gedatolisib in HR+/HER2advanced breast cancer positions the company to potentially enter a significant market. Gedatolisib's mechanism as a multi-target PI3K/AKT/mTOR (PAM) inhibitor differentiates it from existing single-target inhibitors by aiming for more comprehensive pathway blockade, which could address limitations of current treatments. The FDA's Real-Time Oncology Review program underscores the agency's commitment to expediting promising cancer therapies, reflecting broader industry trends towards faster access to innovative treatments.

Comparison to Industry Standards

• The efficacy results for gedatolisib are described by management as "unprecedented" and "potentially practice changing" for patients with HR+/HER2advanced breast cancer.
• The gedatolisib-triplet demonstrated a 76% reduction in the risk of disease progression or death (HR 0.24) and an incremental median PFS improvement of 7.3 months (9.3 months vs. 2.0 months) compared to fulvestrant alone.
• The gedatolisib-doublet showed a 67% reduction in the risk of disease progression or death (HR 0.33) and an incremental median PFS improvement of 5.4 months (7.4 months vs. 2.0 months) compared to fulvestrant alone.
• Gedatolisib's multi-target PAM inhibition mechanism is differentiated from currently approved single-target inhibitors of the PAM pathway, which often lead to cross-activation of uninhibited components, limiting efficacy. Gedatolisib aims for full suppression by minimizing this adaptive cross-activation.

Stakeholder Impact

• Shareholders: Potential for significant value creation if gedatolisib receives FDA approval and is successfully commercialized, given the large market for advanced breast cancer.
• Patients: Offers a potentially "practice changing" new treatment option for HR+/HER2PIK3CA wild-type advanced breast cancer, with demonstrated superior efficacy compared to existing therapies.
• Employees: Positive impact on morale and job security due to significant progress in drug development and potential for future growth.
• Regulatory Authorities: The FDA's RTOR program and prior designations indicate a collaborative and expedited review process for a promising therapy, aligning with public health goals.

Next Steps

• FDA review process for the gedatolisib NDA under the Real-Time Oncology Review (RTOR) program.
• Continued enrollment of patients for the Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR+/HER2ABC.
• Ongoing Phase 1/2 clinical trial (CELC-G-201) evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer.

Key Dates

Recommendation

The submission of an NDA for a drug with Breakthrough Therapy and Fast Track designations, coupled with highly positive Phase 3 clinical data (unprecedented efficacy results and significant PFS improvement), and acceptance into the FDA's Real-Time Oncology Review program, represents a major de-risking event and a significant step towards commercialization. This news strongly suggests a high probability of regulatory approval and substantial future revenue potential, making it a compelling investment opportunity for a seasoned investor.

Keywords

Celcuity, CELC, Gedatolisib, NDA, FDA, Breast Cancer, HR+ HER2-, PIK3CA wild-type, Advanced Breast Cancer, Oncology, Biotechnology, Clinical Trial, VIKTORIA-1, Real-Time Oncology Review, Breakthrough Therapy, Fast Track, PI3K/AKT/mTOR inhibitor, PAM pathway